Search research articles
Contact Us
Filters
Showing results (541-550 of 692) with videos related to
Page
of 70
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2015
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†
A-M C Dingemans, H J M Groen, G J M Herder, et al.
JTO Clinical and Research Reports
|
December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
Liesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
Thorax
|
January 26, 2002
Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals
G J M Herder, P Verboom, E F Smit, et al.
Journal of Clinical Pathology
|
March 31, 2012
Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer
A Jasmijn Hubers, Daniëlle A M Heideman, Gerarda J M Herder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Molecular Tumor Boards: current practice and future needs
D L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 12, 2020
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
B van Veggel, J F Vilacha Madeira R Santos, S M S Hashemi, et al.
Clinical Lung Cancer
|
April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Remi Veillon, Hiroshi Sakai, Xiuning Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
H S Rugo, E Tokunaga, H Iwata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2010
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
A-M C Dingemans, A J de Langen, V van den Boogaart, et al.
Oncotarget
|
May 28, 2015
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Elena Galvani, Jing Sun, Leticia G Leon, et al.
Page
of 70
Search research articles
Search
Showing results (541-550 of 692) with videos related to
Sort By:
Page
of 70
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2015
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†
A-M C Dingemans, H J M Groen, G J M Herder, et al.
JTO Clinical and Research Reports
|
December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
Liesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
Thorax
|
January 26, 2002
Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals
G J M Herder, P Verboom, E F Smit, et al.
Journal of Clinical Pathology
|
March 31, 2012
Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer
A Jasmijn Hubers, Daniëlle A M Heideman, Gerarda J M Herder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Molecular Tumor Boards: current practice and future needs
D L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 12, 2020
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
B van Veggel, J F Vilacha Madeira R Santos, S M S Hashemi, et al.
Clinical Lung Cancer
|
April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Remi Veillon, Hiroshi Sakai, Xiuning Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
H S Rugo, E Tokunaga, H Iwata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2010
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
A-M C Dingemans, A J de Langen, V van den Boogaart, et al.
Oncotarget
|
May 28, 2015
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Elena Galvani, Jing Sun, Leticia G Leon, et al.
Page
of 70